Roche To Buy US Biotech Firm InterMune For $8.3 Billion

The
logo of Swiss pharmaceutical company Roche is seen outside the
Shanghai Roche Pharmaceutical Co. Ltd. headquarters in
ShanghaiThomson
Reuters

LONDON (Reuters) - Roche Holding AG has agreed to buy U.S.
biotech company InterMune Inc for $8.3 billion in cash, marking
the latest multibillion-dollar deal in a consolidating
pharmaceutical sector, Roche said on Sunday.

The Swiss drugmaker will pay $74.00 a share for InterMune,
representing a premium of 38 percent to the closing price on Aug.
22.

(Reporting by Ben Hirschler, Editing by Angus MacSwan)

Read the original article on Reuters. Copyright 2014. Follow Reuters on Twitter.